Dimerix (ASX:DXB) confirmed the first Action3 phase three clinical trial site in Japan is now open for recruitment, triggering the first milestone payment of 400 million yen from Japanese partner Fuso Pharmaceutical Industries, according to a Friday filing with the Australian bourse.
The trial aims to assess the efficacy and safety of the DMX-200 drug candidate in patients with focal segmental glomerulosclerosis kidney disease who are receiving a stable dose of an angiotensin II receptor blocker, the filing said.
The company anticipates receiving the milestone payment from Fuso within 30 days.
Shares rose nearly 2% in morning trade Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.